Cat. No.: DAB-0012333
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human NADK protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NADK |
| UniProt No. | O95544 |
| Gene ID | 65220 |
| Gene Description | NADK, also known as NAD kinase, is a cytoplasmic protein responsible for maintaining the pool of available NADP+ and NADPH within the cell. Using ATP as a phosphate donor, NADK catalyzes the phosphorylation of NAD+ to NADP+. This molecule is then reduced to NADPH and utilized in various metabolic and biosynthetic pathways. NADK has been suggested to play a role in glucose metabolism due to the effect NADPH production has on both the insulin secretion and survival of pancreatic β-cells. NADPH has a vital role in protecting cells from oxidative stress through its neutralizing effect on reactive oxygen species, which also accumulate during cell growth. Along with the p53 tumor suppression protein, NADK has been a suggested target in cancer therapy due its link to NADPH production and its resulting protective role on growing and proliferating cells. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
